Loading...
XSTO
SEZI
Market cap79mUSD
Dec 05, Last price  
4.77SEK
1D
-1.24%
1Q
-26.16%
Jan 2017
-27.98%
IPO
-19.72%
Name

Senzime AB (publ)

Chart & Performance

D1W1MN
XSTO:SEZI chart
P/E
P/S
12.82
EPS
Div Yield, %
Shrs. gr., 5y
19.22%
Rev. gr., 5y
54.18%
Revenues
58m
+63.55%
000298,3431,235,019541,155152,6271,628,000189,0003,214,0006,711,0009,337,00010,980,00014,034,00035,754,00058,477,000
Net income
-119m
L-11.50%
-1,721,470-2,354,674-2,100,326-4,392,512-5,597,835-6,191,678-7,580,563-9,412,000-13,027,000-25,621,000-33,675,000-47,445,000-82,143,000-132,700,000-134,149,000-118,727,000
CFO
-106m
L-7.00%
-1,603,309-2,119,541-1,950,783-6,063,884-5,429,576-3,847,443-6,413,380-10,004,000-12,292,000-17,733,000-27,135,000-38,335,000-81,328,000-136,778,000-113,908,000-105,938,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
IPO date
Jun 18, 2008
Employees
45
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT